Behandlung mit Therapeutischem Antikörper und Interleukin-2 (IL2)
Anmelder: BioNTech SE, TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP4748450
- Anmeldetag
- 22. September 2020
- Veröffentlichung
- 27. Mai 2026
- Rechtsraum
- EP
- IPC
- A61P35/00
Abstract
Tumor cells often evade an immune response, e.g., by reducing or eliminating MHC expression and/or IFN-signaling, which enables uncontrolled growth. We demonstrate herein that antibody-based immunotherapy in combination with IL2 administration is an effective therapy against such resistant tumors. Specifically, the present disclosure relates to methods of treating a subject with cancer that is at least partially resistant to an MHC-dependent T cell response comprising administering to the subject: a. a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof; and b. antibody-based immunotherapy.
Anmelder
- Firmen
- BioNTech SE
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH - Land
- 🇩🇪 Deutschland